ARAnna Rodziewicz-Konarska

Anna Rodziewicz-Konarska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Rodziewicz-Konarska has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment Outcomes and Prognostic Factors in Children with Myeloid Leukemia Associated with Down Syndrome: A Nationwide Polish Retrospective Study

    by Katarzyna Pawińska-Wąsikowska, Małgorzata Czogała, Karolina Bukowska-Strakova, Teofila Książek, Agnieszka Pac, Magdalena Samborska, Jacek Wachowiak, Anna Tomoń, Radosław Chaber, Karolina Zielezińska, et al.

    Background: Significant progress has been achieved in the treatment of children with myeloid leukemia associated with Down syndrome (ML-DS). We aimed to evaluate treatment outcomes and prognostic factors in children with ML-DS treated in Poland. Methods: Thirty-six children with ML-DS treated at pediatric hematology and oncology centers in Poland according to the ML-DS 2006 protocol based on the AML-BFM backbone between 2015 and 2024 were retrospectively analyzed. Results: The estimated 5-year event-free survival (EFS) and overall survival (OS) were 84.3% (95%CI: 72.5–98.1%) and 87.9% (77.4–99.8%), respectively. Although children with a complex karyotype showed numerically lower survival estimates than those with isolated constitutional trisomy 21 or additional cytogenetic abnormalities (OS: 60% [95%CI: 29.3–100%] vs. 90% [73.2–100%] vs. 92.3% [78.9–100%], p = 0.24; EFS: 60% [95%CI: 29.3–100%) vs. 75% [49.6–100%] vs. 92.3% [78.9–100%], p = 0.26), p = 0.26), these differences were not statistically significant. MRD positivity (≥0.1%) after the second induction cycle was identified as an adverse prognostic factor in the univariable analysis (HR = 31.1, 95%CI: 2.74–353.2; p = 0.006). Conclusions: Persistent MRD positivity after the second induction cycle may identify children with ML-DS at increased risk of treatment failure. Larger multicenter studies are needed to validate the prognostic significance of MRD and recurrent molecular alterations to optimize risk-adapted treatment strategies.

  • Open Access

    Characteristics and Outcome of FLT3-ITD-Positive Pediatric Acute Myeloid Leukemia—Experience of Polish Pediatric Leukemia and Lymphoma Study Group from 2005 to 2022

    by Małgorzata Czogała, Wojciech Czogała, Katarzyna Pawińska-Wąsikowska, Teofila Książek, Karolina Bukowska-Strakova, Barbara Sikorska-Fic, Paweł Łaguna, Anna Fałkowska, Katarzyna Drabko, Katarzyna Muszyńska-Rosłan, et al.

    Background: The FMS-like tyrosine kinase 3 (FLT3) gene mutated in 10–15% of pediatric acute myeloid leukemia (AML) is associated with an inferior outcome. The aim of the study was to analyze the outcome and characteristics of FLT3-ITD-positive pediatric AML. Methods: We retrospectively analyzed the nationwide pediatric AML database from between 2005 and 2022. FLT3-ITD was found in 54/497 (10.7%) patients with available analysis. Three consecutive treatment protocols were used (AML-BFM 2004 Interim, AML-BFM 2012 Registry, AML-BFM 2019 recommendations). Results: Probabilities of 5-year overall (OS), event-free (EFS) and relapse-free survival were significantly lower in the FLT3-ITD-positive patients compared to FLT3-ITD-negative (0.54 vs. 0.71, p = 0.041; 0.36 vs. 0.59, p = 0.0004; 0.47 vs. 0.70, p = 0.0029, accordingly). An improvement in the outcome was found in the analyzed period of time, with a trend of better survival in patients treated under the AML-BFM 2012 and AML-BFM 2019 protocols compared to the AML-BFM 2004 protocol (5-year EFS 0.52 vs. 0.27, p = 0.069). There was a trend of improved outcomes in patients treated with FLT3 inhibitors (n = 9, 2-year EFS 0.67 vs. 0.33, p = 0.053) and those who received stem cell transplantation (SCT) (n = 26; 5-year EFS 0.70 vs. 0.27, p = 0.059). The co-occurrence of the WT1 mutation had a dismal impact on the prognosis (5-year EFS 0.23 vs. 0.69, p = 0.002), while the NPM1 mutation improved survival (5-year OS 1.0 vs. 0.44, p = 0.036). Conclusions: It seems that SCT and FLT3 inhibitors have a beneficial impact on the prognosis. Additional genetic alterations, like the WT1 and NPM1 mutations, significantly influence the outcome.


  • Open Access

    Pediatric Acute Myeloid Leukemia Post Cytotoxic Therapy—Retrospective Analysis of the Patients Treated in Poland from 2005 to 2022

    by Małgorzata Czogała, Wojciech Czogała, Katarzyna Pawińska-Wąsikowska, Teofila Książek, Karolina Bukowska-Strakova, Barbara Sikorska-Fic, Paweł Łaguna, Jolanta Skalska-Sadowska, Jacek Wachowiak, Anna Rodziewicz-Konarska, et al.

    Acute P./myeloid leukemia post cytotoxic therapy (AML-pCT) is rare complication of cancer treatment in childhood. The objective of the study was to identify clinical characteristics and provide an analysis of the outcomes in pediatric AML-pCT. We retrospectively analyzed the data of 40 children with AML-pCT, treated from 2005 to 2020 within the Polish Pediatric Leukemia and Lymphoma Study Group. The most common primary malignancies were acute lymphoblastic leukemia (32.5%) and brain tumors (20%). The median latency period was 2.9 years (range: 0.7–12.9). Probabilities of overall (OS), event-free (EFS), and relapse-free survival (RFS) in the whole cohort were 0.49 ± 0.08, 0.43 ± 0.08, and 0.64 ± 0.10, respectively. Significant improvements in outcomes were observed in patients treated from 2015–2022 (two induction cycles followed by stem cell transplantation—SCT in 69% of patients) compared to 2005–2014 (four induction cycles followed by SCT in 49% of patients). The probability of EFS increased from 0.30 ± 0.10 to 0.67 ± 0.12 (p = 0.07) and RFS increased from 0.46 ± 0.11 to 1.0 (p = 0.01). The poorest outcome (OS and EFS 0.25 ± 0.20) was in AML post brain tumor, mainly due to deaths from toxicities. To conclude, treatment results achieved in patients with AML-pCT treated from 2015–2022, with two induction cycles followed by immediate SCT, were better than those reported by other authors, and comparable to the results in de novo AML.